Mater Clinical Trials
Mater conducts clinical trials in a range of therapeutic areas including Cancer, Neurology, Medicine, Orthopaedics Surgery and Acute Care, and Mothers’ and Babies Health. Clinical trials are an essential component of healthcare. They provide the evidence to evaluate the safety and efficacy of new treatments and diagnostics, and provide alternative treatment options for patients with unmet needs.
Mater currently has over 200 active clinical trials. These trials include commercial pharmaceutical and medical device studies, as well as collaborative group studies and investigator-initiated studies, led by Mater’s researchers and collaborators at The University of Queensland and other leading Australian and international medical research institutions.
Without volunteers, clinical trials are not possible. If you are interested in being involved – you may be a patient with a new diagnosis, a patient with a long term diagnosis or a healthy volunteer – view available trials below or contact the Mater Clinical Trials team.
Clinical Trials are divided into the following categories:
A study to find out whether BI 1015550 improves lung function in people with Idiopathic Pulmonary Fibrosis.
A clinical trial of investigational drug tafasitamab plus lenalidomide in addition to standard therapy for treatment of newly diagnosed high and intermediate risk diffuse large B-cell lymphoma (DLBCL)
Trial Status:
Active, not recruiting
|
A clinical trial to evaluate the efficacy, safety and bioavailability of GDC-6599 in patients with chronic cough.
Trial Status:
Active, not recruiting
|
Heated versus room temperature intra-peritoneal chemotherapy at the time of for stage III ovarian cancer surgical cytoreduction
iSEARCH is a multicentre randomised controlled trial (RCT) aiming to improve outcomes for women and babies.
Continuous Positive Air Pressure Interface (Prongs & Masks) for Newborns - Product Evaluation Study
Trial Status:
Active, not recruiting
|
Evaluating the efficacy and safety of post surgical Giredestrant compared with doctors choice of endocrine therapy (Tamoxifen, Anastrozole, Letrozole or Exemestane) in patients with estrogen receptor−positive, HER2-negative early breast cancer.
Evaluating the efficacy and safety of post surgical Giredestrant compared with doctors choice of endocrine therapy (Tamoxifen, Anastrozole, Letrozole or Exemestane) in patients with estrogen receptor−positive, HER2-negative early breast cancer.
A clinical trial to investigate the efficacy, safety and tolerability of ML-004 for treatment of the core behavioural symptoms in Autistic people
Medicinal cannabis to relieve symptoms of advanced cancer in palliative care patients